Navigation Links
Alan Ashworth to receive award for his breakthrough work in breast cancer
Date:4/22/2010

Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.

"I'm both surprised and delighted that the Waxman Foundation has thought to honor me in this way," said Dr. Ashworth. "Recognition from your peers is incredibly important and I'm thrilled."

Dr. Ashworth helped discover the BRCA2 breast cancer gene in 1995. After realizing that BRCA-related cancers had a flawed DNA repair pathway, Dr. Ashworth and his team worked with a biotechnology company to study the use of PARP inhibitors to treat these cancers. They learned that BRCA-defective cancer cells were 1,000 times more sensitive to PARP inhibitors than cells that were normal. His lab is studying the use of PARP inhibitors to treat cancers such as endometrial cancer, ovarian cancer and breast cancer, including triple-negative breast cancer, which responds poorly to normal chemotherapy.

Speaking about Dr. Ashworth's research in triple-negative breast cancer, Samuel Waxman, M.D., the Scientific Director of the Waxman Foundation said it represents a contribution from a scientist unraveling a genomic defect in breast cancer that has resulted in a novel treatment for women who would otherwise have a poor prognosis.

Michael Nierenberg, the Chair of the Foundation added, "The Waxman Foundation is committed to bridging the gap between lab science and the patient. We are excited to help further the important work of Dr. Ashworth and his lab."

Recent recipients of the Workman Award include Stephen Baylin, M.D., and Peter Jones, Ph.D., in 2008 for the development of demethylating agents and epigenetic therapy for hematologic malignancies and Douglas Lowy, M.D.,
'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
212-348-0136
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Rutgers Genetics receives $7.8 million for autism research
2. Herr receives Heinz Award for Technology, the Economy and Employment
3. UCI receives $5M from Edwards Lifesciences
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
6. UC Riverside biologist receives prestigious MacArthur Fellowship
7. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
8. Penn biochemist receives NIH New Innovators Award
9. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
10. K-State chemistry professor to receive Masao Horiba award
11. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/22/2013)... CITY, May 22, 2013 U.S. Forest Service scientists ... that, with funding from the TKF Foundation, will examine ... communities and individuals recover from tragedy. , The TKF ... of six projects selected for grant funding. In addition ... sacred spaces in recovery and resiliency, the 3-year, $585,000 ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 19 2011) Bone marrow-derived stem cells (BMDCs) have been ... to different cell populations in a variety of organs under ... aimed at repairing damaged brain tissue or helping to restore ... to the cerebellum at the back of the brain. In ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
... (IRSF) announced today that it is awarding over $1.5M to ... diverse topics from basic science and disease pathology to developing ... the world,s largest private source of funding for biomedical and ... spending of over $26M since 1998. It is the ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3
(Date:5/23/2013)... 23, 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ... will host a teleconference to discuss its First Quarter ... The teleconference information is provided below: Date: ... Time (EDT) Dial-in: (800) 875-3456 (U.S.); (800) ... Passcode: VS22823 For those unable to participate ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), manufacturer of ... CE (Europe) approved Total Artificial Heart, announced today that ... than 380,000 visitors annually, is featuring the SynCardia ... portable driver as part of its $3 million Bodyworks ... kind. , “BodyWorks combines the latest technology with ...
(Date:5/23/2013)... 2013 Bed bugs already cost Alton Housing ... still ongoing, a report from kmov.com suggested that the said ... bug treatment. Meanwhile, to be of help, My Cleaning Products ... bed bug exterminator service. , The report, which ... so far spent $35,000 for bed bug elimination, ...
Breaking Biology Technology:Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... Jan. 26 WellCentive, LLC,today announced that WellCentive ... Information Exchange) as its patient registry and disease,management ... use of WellCentive Registry, more than 1,000 my1HIE ... will be better able to,provide preventive care services ...
... Jan. 26 Sirion Therapeutics, Inc., a privately held ... Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been ... Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... caused by the herpes simplex virus. The FDA has ...
... YORK, Jan. 26 Netsmart Technologies, Inc., a ... health and human services organizations, today announced it ... the New York State Association of Alcoholism and ... company,s comprehensive education, online learning and learning management ...
Cached Biology Technology:my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
Biology Products: